AgNovos Bioscience

AgNovos Bioscience develops novel regenerative therapies and devices for the treatment of osteoporosis and related bone diseases. Its lead product, the OSSURE™ Local Osteo-enhancement Procedure (LOEP) kit—using a proprietary calcium-based biomaterial—is designed to immediately and durably increase bone density and strength at targeted sites. Clinical research demonstrates substantial improvements in treated bones. The company’s pipeline includes an investigational device for vertebral compression fractures that has received both FDA Breakthrough Device designation and IDE approval. The RESTORE trial evaluates the impact of their technology on secondary hip fracture risk—the largest such study in orthopedic traumatology to date.